SQUAWK/NEWS
Account
Account
Menu
Live NewsArchive2026-07-28

Tue, Jul 28, 2026 - Page 14

2404 indexed SquawkNews stories from this UTC day. Showing 1561-1679.

EQUITY 1186EARNINGS 674GEOPOLITICS 169ENERGY 95CENTRAL_BANK 75RATES 71MACRO 49MNA 26COMMODITIES 22REGULATION 21FX 16
L INSP Initiated Sell W/$39.00 PT at UBS INSP Initiated Sell W/$39.00 PT at UBS EQUITY | Jul 28, 2026, 11:49 AM UTC L IART Initiated Neutral W/$19.00 PT at UBS IART Initiated Neutral W/$19.00 PT at UBS EQUITY | Jul 28, 2026, 11:49 AM UTC L GXO Initiated Overweight W/$18.00 PT at Wells Fargo GXO Initiated Overweight W/$18.00 PT at Wells Fargo EQUITY | Jul 28, 2026, 11:49 AM UTC L GMED Initiated Neutral W/$82.00 PT at UBS GMED Initiated Neutral W/$82.00 PT at UBS EQUITY | Jul 28, 2026, 11:49 AM UTC L GKOS Initiated Neutral at UBS GKOS Initiated Neutral at UBS EQUITY | Jul 28, 2026, 11:49 AM UTC L EW Initiated Buy W/$110.00 PT at UBS EW Initiated Buy W/$110.00 PT at UBS EQUITY | Jul 28, 2026, 11:49 AM UTC L COO Initiated Neutral W/$75.00 PT at UBS COO Initiated Neutral W/$75.00 PT at UBS EQUITY | Jul 28, 2026, 11:49 AM UTC L BNTC Initiated Outperform W/$16.00 PT at Wedbush BNTC Initiated Outperform W/$16.00 PT at Wedbush EQUITY | Jul 28, 2026, 11:49 AM UTC L BLCO Initiated Buy at UBS BLCO Initiated Buy at UBS EQUITY | Jul 28, 2026, 11:49 AM UTC L BDX Initiated Buy W/$190.00 PT at UBS BDX Initiated Buy W/$190.00 PT at UBS EQUITY | Jul 28, 2026, 11:49 AM UTC L ATEX Initiated Buy W/$161.00 PT at Clear Street ATEX Initiated Buy W/$161.00 PT at Clear Street EQUITY | Jul 28, 2026, 11:49 AM UTC L ATEC Initiated Buy W/$15.00 PT at UBS ATEC Initiated Buy W/$15.00 PT at UBS EQUITY | Jul 28, 2026, 11:49 AM UTC L XOM Downgrade from Buy to Neutral W/$158.00 PT (from $154.00) at BOFA Securities XOM Downgrade from Buy to Neutral W/$158.00 PT (from $154.00) at BOFA Securities EQUITY | Jul 28, 2026, 11:49 AM UTC L RXO Downgrade from Hold to Sell W/$19.00 PT (from $24.00) at TD Cowen RXO Downgrade from Hold to Sell W/$19.00 PT (from $24.00) at TD Cowen EQUITY | Jul 28, 2026, 11:49 AM UTC L PINE Downgrade from Strong Buy to Outperform W/$22.00 PT at Raymond James PINE Downgrade from Strong Buy to Outperform W/$22.00 PT at Raymond James EQUITY | Jul 28, 2026, 11:49 AM UTC L LEVI Downgrade from Overweight to Equal Weight W/$25.00 PT at Wells Fargo LEVI Downgrade from Overweight to Equal Weight W/$25.00 PT at Wells Fargo EQUITY | Jul 28, 2026, 11:49 AM UTC L INTU Downgrade from Buy to Hold W/$304.00 PT (from $504.00) at TD Cowen INTU Downgrade from Buy to Hold W/$304.00 PT (from $504.00) at TD Cowen EQUITY | Jul 28, 2026, 11:49 AM UTC L FMS Downgrade from Neutral to Underperform W/$19.90 PT at BNP Paribas Exane FMS Downgrade from Neutral to Underperform W/$19.90 PT at BNP Paribas Exane EQUITY | Jul 28, 2026, 11:49 AM UTC L FBRX Downgrade from Overweight to Equalweight W/$77.00 PT (from $74.00) at Barclays FBRX Downgrade from Overweight to Equalweight W/$77.00 PT (from $74.00) at Barclays EQUITY | Jul 28, 2026, 11:49 AM UTC L EBC Downgrade from Overweight to Equal Weight at Stephens EBC Downgrade from Overweight to Equal Weight at Stephens EQUITY | Jul 28, 2026, 11:49 AM UTC L CRNX Downgrade from Buy to Neutral W/$85.00 PT (from $55.00) at UBS CRNX Downgrade from Buy to Neutral W/$85.00 PT (from $55.00) at UBS EQUITY | Jul 28, 2026, 11:49 AM UTC L CLX Downgrade from Buy to Hold W/$98.00 PT (from $125.00) at Jefferies CLX Downgrade from Buy to Hold W/$98.00 PT (from $125.00) at Jefferies EQUITY | Jul 28, 2026, 11:49 AM UTC L CAPR Downgrade from Buy to Neutral at Alliance Global Partners CAPR Downgrade from Buy to Neutral at Alliance Global Partners EQUITY | Jul 28, 2026, 11:49 AM UTC L BMRC Downgrade from Buy to Neutral at Brean Capital BMRC Downgrade from Buy to Neutral at Brean Capital EQUITY | Jul 28, 2026, 11:49 AM UTC L ACI Downgrade from Buy to Neutral W/$12.00 PT (from $20.00) at UBS ACI Downgrade from Buy to Neutral W/$12.00 PT (from $20.00) at UBS EQUITY | Jul 28, 2026, 11:49 AM UTC L SOLV Upgrade from Neutral to Buy W/$95.00 PT at UBS SOLV Upgrade from Neutral to Buy W/$95.00 PT at UBS EQUITY | Jul 28, 2026, 11:49 AM UTC L RELL Upgrade from Market Perform to Outperform W/$24.00 PT at Northland RELL Upgrade from Market Perform to Outperform W/$24.00 PT at Northland EQUITY | Jul 28, 2026, 11:49 AM UTC L NTR Upgrade from Neutral to Outperform W/$80.00 PT at BNP Paribas Exane NTR Upgrade from Neutral to Outperform W/$80.00 PT at BNP Paribas Exane EQUITY | Jul 28, 2026, 11:49 AM UTC L MGY Upgrade from Hold to Buy W/$33.00 PT at Truist Securities MGY Upgrade from Hold to Buy W/$33.00 PT at Truist Securities EQUITY | Jul 28, 2026, 11:49 AM UTC L MDT Upgrade from Neutral to Buy W/$100.00 PT at UBS MDT Upgrade from Neutral to Buy W/$100.00 PT at UBS EQUITY | Jul 28, 2026, 11:49 AM UTC L IP Upgrade from Neutral to Overweight W/$61.00 PT (from $51.00) at JPMorgan IP Upgrade from Neutral to Overweight W/$61.00 PT (from $51.00) at JPMorgan EQUITY | Jul 28, 2026, 11:49 AM UTC L HON Upgrade from Underperform to Neutral W/$265.00 PT (from $205.00) at BOFA Securities HON Upgrade from Underperform to Neutral W/$265.00 PT (from $205.00) at BOFA Securities EQUITY | Jul 28, 2026, 11:49 AM UTC L FLY Upgrade from N/A to Overweight W/$50.00 PT at KeyBanc FLY Upgrade from N/A to Overweight W/$50.00 PT at KeyBanc EQUITY | Jul 28, 2026, 11:49 AM UTC L CIB Upgrade from Neutral to Buy W/$98.00 PT (from $81.00) at Goldman Sachs CIB Upgrade from Neutral to Buy W/$98.00 PT (from $81.00) at Goldman Sachs EQUITY | Jul 28, 2026, 11:49 AM UTC H MergerBrief Daily: Deal News CHTR/LBRDA: CHTR Automatic Shelf Prospectus (Filing) OPFI/BNCC: Form S-4 Filed (S-4) NEE/D: Employee podcast tr MergerBrief Daily: Deal News CHTR/LBRDA: CHTR Automatic Shelf Prospectus (Filing) OPFI/BNCC: Form S-4 Filed (S-4) NEE/D: Employee podcast transcript on integration planning and culture (PR) Global Infrastructure/AES: Aud EQUITY | Jul 28, 2026, 11:47 AM UTC L BAX DXCM ENOV HSIC NUE OVV OZK TFII ABT AMZN ATRC BBNX BKR BSX CEG MCB NRG RXST SGHT TNDM VST PT changes @ UBS BAX DXCM ENOV HSIC NUE OVV OZK TFII ABT AMZN ATRC BBNX BKR BSX CEG MCB NRG RXST SGHT TNDM VST PT changes @ UBS EQUITY | Jul 28, 2026, 11:47 AM UTC L CMND - Clearmind Medicine Successfully Completes Part A of its FDA Regulated Phase I/II Trial CMND - Clearmind Medicine Successfully Completes Part A of its FDA Regulated Phase I/II Trial REGULATION | Jul 28, 2026, 11:47 AM UTC L CLX downgraded from Buy to Hold W/ $98 PT (from $125) @ JEFF CLX downgraded from Buy to Hold W/ $98 PT (from $125) @ JEFF EQUITY | Jul 28, 2026, 11:46 AM UTC L Kiniksa raises FY26 revenue view to $980M-$995M from $930M-$945M Consensus $940.13M. The... EARNINGS | Jul 28, 2026, 11:46 AM UTC L CVLT Commvault Systems RESULTS: Q1, Q1 arr $1.054B, Q1 REV $100M vs. EST $310.4M CVLT Commvault Systems RESULTS: Q1, Q1 arr $1.054B, Q1 REV $100M vs. EST $310.4M EARNINGS | Jul 28, 2026, 11:45 AM UTC L CVLT CVLT - Commvault Announces First Quarter Fiscal 2027 Financial Results CVLT CVLT - Commvault Announces First Quarter Fiscal 2027 Financial Results EARNINGS | Jul 28, 2026, 11:45 AM UTC L FMS downgraded fro Neutral to Underperform @ BNP FMS downgraded fro Neutral to Underperform @ BNP EQUITY | Jul 28, 2026, 11:45 AM UTC L LTRN Lantern Pharma to advance EMA-cleared phase 1B/2 trial of lp-184 (zirdafulven) in biomarker-selected advanced bladder cancer LTRN Lantern Pharma to advance EMA-cleared phase 1B/2 trial of lp-184 (zirdafulven) in biomarker-selected advanced bladder cancer EQUITY | Jul 28, 2026, 11:45 AM UTC L Kiniksa reports Q2 EPS 30c, consensus 28c Reports Q2 revenue... EARNINGS | Jul 28, 2026, 11:45 AM UTC L KGS new Overweight W/ $78 PT @ Piper KGS new Overweight W/ $78 PT @ Piper EQUITY | Jul 28, 2026, 11:44 AM UTC L REPL -21% premarket after FDA headlines REPL -21% premarket after FDA headlines REGULATION | Jul 28, 2026, 11:44 AM UTC L Japan Defense Force On Rescue Mission At Quake-Hit Mall - TBS Japan Defense Force On Rescue Mission At Quake-Hit Mall - TBS EQUITY | Jul 28, 2026, 11:43 AM UTC L CIB upgraded from Neutral to Buy W/ $98 PT (form $81) @ GSCO CIB upgraded from Neutral to Buy W/ $98 PT (form $81) @ GSCO EQUITY | Jul 28, 2026, 11:43 AM UTC L TE -9% premarket after preliminary results TE -9% premarket after preliminary results EQUITY | Jul 28, 2026, 11:43 AM UTC L AMZN - Business Insider earlier: Amazon overhauls its AI strategy, winding down most flagship models -Amazon is winding down most of its Nov AMZN - Business Insider earlier: Amazon overhauls its AI strategy, winding down most flagship models -Amazon is winding down most of its Nova in-house AI models. -Amazon's AGI team was hit by layoffs. -SVP Peter DeSantis EQUITY | Jul 28, 2026, 11:43 AM UTC L FBRX downgraded to EW from Overweight after ARGX M&A headlines @ BARC FBRX downgraded to EW from Overweight after ARGX M&A headlines @ BARC MNA | Jul 28, 2026, 11:42 AM UTC L SIGI Downgrade from Outperform to Market Perform W/$97.00 PT at BMO Capital SIGI Downgrade from Outperform to Market Perform W/$97.00 PT at BMO Capital EQUITY | Jul 28, 2026, 11:41 AM UTC M Is the AI Boom A 'Virtuous Circle' Or a Ponzi Scheme? Wall Street Is Split The artificial intelligence boom has sparked a web of interwoven investments, leaving market watchers divided on whether this trend represents a “virtuous circle” of strategic alignment or a perilous tech echo chamber ma RATES | Jul 28, 2026, 11:41 AM UTC L Dyne Therapeutics receives FDA clearance to initiate DYNE-302 trial Dyne Therapeutics... REGULATION | Jul 28, 2026, 11:41 AM UTC L TSLA ContourGlobal says Tesla signed a long-term agreement to buy 90% of Project Sterling’s electricity. The Arizona solar-and-storage TSLA ContourGlobal says Tesla signed a long-term agreement to buy 90% of Project Sterling’s electricity. The Arizona solar-and-storage development is owned by KKR-backed ContourGlobal. Scheduled to begin operating FX | Jul 28, 2026, 11:41 AM UTC L REPL FDA staff reviewers Flag concerns regarding Replimune's cancer drug trial ahead of July 30 advisory committee meeting - briefing docs REPL FDA staff reviewers Flag concerns regarding Replimune's cancer drug trial ahead of July 30 advisory committee meeting - briefing docs REGULATION | Jul 28, 2026, 11:41 AM UTC L PGNY downgraded to EW from OW, but raise PT to $34 from $27 @ BARC PGNY downgraded to EW from OW, but raise PT to $34 from $27 @ BARC EQUITY | Jul 28, 2026, 11:41 AM UTC L NVO high risk, high reward into Ph3 ZEUS CV readout @ BMO NVO high risk, high reward into Ph3 ZEUS CV readout @ BMO EQUITY | Jul 28, 2026, 11:41 AM UTC L PINE downgraded from Strong Buy to Outperform W/ $22 PT @ RAJA PINE downgraded from Strong Buy to Outperform W/ $22 PT @ RAJA EQUITY | Jul 28, 2026, 11:41 AM UTC L USO off lows USO off lows EQUITY | Jul 28, 2026, 11:40 AM UTC L AMZN Reiterate Outperform, top pick, $360 PT (from $355) – insatiable compute demand and resilient consumer @ BMO AMZN Reiterate Outperform, top pick, $360 PT (from $355) – insatiable compute demand and resilient consumer @ BMO EQUITY | Jul 28, 2026, 11:40 AM UTC L FSS - Federal Signal Corporation Declares Dividend of $0.15 per share FSS - Federal Signal Corporation Declares Dividend of $0.15 per share EQUITY | Jul 28, 2026, 11:40 AM UTC L TSLA - TESLA TO BUY POWER FROM KKR-BACKED ARIZONA SOLAR, BATTERY PLANT TSLA - TESLA TO BUY POWER FROM KKR-BACKED ARIZONA SOLAR, BATTERY PLANT EQUITY | Jul 28, 2026, 11:40 AM UTC L JBS upgraded from Neutral to Overweight W/ $18 PT @ JPMC JBS upgraded from Neutral to Overweight W/ $18 PT @ JPMC EQUITY | Jul 28, 2026, 11:40 AM UTC L XIFR xplr infrastructure: Q2 EPS from cont ops $0.40 - Q2 operating revenues $363M XIFR xplr infrastructure: Q2 EPS from cont ops $0.40 - Q2 operating revenues $363M EARNINGS | Jul 28, 2026, 11:39 AM UTC H KYIV Reiterate Buy and $20 PT heading into Q2 as expect Kyivstar stock to continue to benefit from exemplary underlying operating performanc KYIV Reiterate Buy and $20 PT heading into Q2 as expect Kyivstar stock to continue to benefit from exemplary underlying operating performance coupled with heightened Frontier market investor interest in Ukraine @ Benchma GEOPOLITICS | Jul 28, 2026, 11:39 AM UTC H Hubbell raises FY26 adjusted EPS view to $20.25-$20.55 from $19.30-$19.85 Consensus $19.97. The... EARNINGS | Jul 28, 2026, 11:38 AM UTC L INTU downgraded from Buy to Hold W/ $304 PT (from $504) @ TDCowen INTU downgraded from Buy to Hold W/ $304 PT (from $504) @ TDCowen EQUITY | Jul 28, 2026, 11:38 AM UTC L RXO's valuation has become more attractive following the fallout from the Lipe V. Lupus Superior verdict, in which a jury awarded approximat RXO's valuation has become more attractive following the fallout from the Lipe V. Lupus Superior verdict, in which a jury awarded approximately $604M against Lupus Superior, its driver, and CHRW @ Benchmark EQUITY | Jul 28, 2026, 11:38 AM UTC L PHIN - PHINIA to Participate in Deutsche Bank Chicago Industrials Summit PHIN - PHINIA to Participate in Deutsche Bank Chicago Industrials Summit EQUITY | Jul 28, 2026, 11:38 AM UTC L BSP - Bending Spoons enters into €500 million SACE-backed term loan facility BSP - Bending Spoons enters into €500 million SACE-backed term loan facility EQUITY | Jul 28, 2026, 11:38 AM UTC L ESI maintain Outperform, top pick, $50 PT after results @ BMO ESI maintain Outperform, top pick, $50 PT after results @ BMO EQUITY | Jul 28, 2026, 11:38 AM UTC L BODI - The Beachbody Company, Inc. Announces Second Quarter 2026 Earnings Release Date, Conference Call, and Webcast BODI - The Beachbody Company, Inc. Announces Second Quarter 2026 Earnings Release Date, Conference Call, and Webcast EARNINGS | Jul 28, 2026, 11:38 AM UTC L LPRO - Open Lending and ANV Announce Results of Tender Offer LPRO - Open Lending and ANV Announce Results of Tender Offer EQUITY | Jul 28, 2026, 11:38 AM UTC L Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout. re RATES | Jul 28, 2026, 11:38 AM UTC L ACI downgraded from Buy to Neutral W/ $12 PT (from $20) @ UBS ACI downgraded from Buy to Neutral W/ $12 PT (from $20) @ UBS EQUITY | Jul 28, 2026, 11:38 AM UTC L Japan’s Minimum Wage For Fiscal 2026 Set To National Average Of 1,176 Yen, Up 55 Yen – Nikkei READ HERE EQUITY | Jul 28, 2026, 11:38 AM UTC H Hubbell reports Q2 adjusted EPS $5.52, consensus $5.38 Reports Q2 revenue... EARNINGS | Jul 28, 2026, 11:37 AM UTC L GSK sees 2031 sales over GBP 40B Accelerating growth from... EQUITY | Jul 28, 2026, 11:37 AM UTC L Japan targets minimum wage of 1,176 Yen/hour for FY26 - Nikkei Japan targets minimum wage of 1,176 Yen/hour for FY26 - Nikkei FX | Jul 28, 2026, 11:36 AM UTC L TCOM Regulatory Reset, Long-Term Opportunity Remains; Buy @ Benchmark TCOM Regulatory Reset, Long-Term Opportunity Remains; Buy @ Benchmark EQUITY | Jul 28, 2026, 11:36 AM UTC L MPLT maintain Outperform, though lower PT to $20 (from $46) after ZEPHYR data setback @ BMO MPLT maintain Outperform, though lower PT to $20 (from $46) after ZEPHYR data setback @ BMO EQUITY | Jul 28, 2026, 11:36 AM UTC L GSK sees FY26 core EPS growth 7%-9% Expect 2026 turnover... EARNINGS | Jul 28, 2026, 11:36 AM UTC L XIFR xplr infrastructure: for 2026, expect portfolio to deliver adj EBITDA\nof $1.75B to $1.95B and fcfbg of $600M to $700M XIFR xplr infrastructure: for 2026, expect portfolio to deliver adj EBITDA\nof $1.75B to $1.95B and fcfbg of $600M to $700M EQUITY | Jul 28, 2026, 11:36 AM UTC L Paypal Q2 2026 Earnings Paypal Q2 2026 Earnings EARNINGS | Jul 28, 2026, 11:35 AM UTC L RMBS Reiterate Buy and $165 PT Following better-than-expected Q226 results and in line Q326 guidance, @ Benchmark RMBS Reiterate Buy and $165 PT Following better-than-expected Q226 results and in line Q326 guidance, @ Benchmark EARNINGS | Jul 28, 2026, 11:35 AM UTC H TTWO Reiterate Outperform, top pick, $285 PT into earnings @ BMO TTWO Reiterate Outperform, top pick, $285 PT into earnings @ BMO EARNINGS | Jul 28, 2026, 11:34 AM UTC L BA (more) Oper cash flow $1.36B, est. $687.7M BA (more) Oper cash flow $1.36B, est. $687.7M EQUITY | Jul 28, 2026, 11:34 AM UTC L HUBB Q2’26 EARNINGS HIGHLIGHTS Revenue: $1.71B (Est. $1.65B); +15% YoY Adj. EPS: $5.52 (Est. $5.38); +12% YoY Organic Net Sales Growth HUBB Q2’26 EARNINGS HIGHLIGHTS Revenue: $1.71B (Est. $1.65B); +15% YoY Adj. EPS: $5.52 (Est. $5.38); +12% YoY Organic Net Sales Growth: +10% EARNINGS | Jul 28, 2026, 11:34 AM UTC L YARW new Buy @ TDCowen YARW new Buy @ TDCowen EQUITY | Jul 28, 2026, 11:33 AM UTC H $BA Boeing Q2 Earnings $BA Boeing Q2 Earnings EARNINGS | Jul 28, 2026, 11:33 AM UTC L KURA Reiterate Market Outperform, $24 PT after investor event @ Citizens KURA Reiterate Market Outperform, $24 PT after investor event @ Citizens EQUITY | Jul 28, 2026, 11:33 AM UTC H USO OPEC+ expects to hold 2026 output steady after Sept: delegates USO OPEC+ expects to hold 2026 output steady after Sept: delegates ENERGY | Jul 28, 2026, 11:32 AM UTC L Red Sea Tanker Traffic Hits Multi-Month Low as Houthi Threat Holds Red Sea Tanker Traffic Hits Multi-Month Low as Houthi Threat Holds ENERGY | Jul 28, 2026, 11:31 AM UTC L KZIA Kazia Therapeutics announces the filing of provisional patent for novel strategy, supported by preclinical data, to prevent metastatic KZIA Kazia Therapeutics announces the filing of provisional patent for novel strategy, supported by preclinical data, to prevent metastatic recurrence in triple-negative breast cancer EQUITY | Jul 28, 2026, 11:31 AM UTC L GSK reports Q2 core EPS 50.5p, up 9% at CER Reports Q2 revenue GBP... EARNINGS | Jul 28, 2026, 11:31 AM UTC H Boeing reports Q2 core EPS (76c), consensus (31c) Reports Q2 revenue... EARNINGS | Jul 28, 2026, 11:31 AM UTC H Hubbell Lowers FY2026 GAAP EPS Guidance from $17.45-$18.00 to $17.25-$17.55 vs $17.78 Est Hubbell (NYSE: HUBB ) lowers FY2026 GAAP EPS guidance from $17.45-$18.00 to $17.25-$17.55 vs $17.78 analyst estimate.. EARNINGS | Jul 28, 2026, 11:31 AM UTC H Hubbell Raises FY2026 Adj EPS Guidance from $19.30-$19.85 to $20.25-$20.55 vs $19.75 Est; Raises FY2026 Sales Guidance from $6.313B-$6.488B Hubbell (NYSE: HUBB ) raises FY2026 Adj EPS guidance from $19.30-$19.85 to $20.25-$20.55 vs $19.75 analyst estimate. Raises FY2026 sales outlook from $6.313 billion-$6.488 billion to $6.780 billion-$6.897 billion vs $6.5 EARNINGS | Jul 28, 2026, 11:31 AM UTC H OPEC+ Expects To Hold 2026 Output Steady After Sept - Delegates OPEC+ Expects To Hold 2026 Output Steady After Sept - Delegates ENERGY | Jul 28, 2026, 11:31 AM UTC L Kiniksa Pharmaceuticals Raises FY2026 Sales Guidance from $930.000M-$945.000M to $980.000M-$995.000M vs $940.106M Est Kiniksa Pharmaceuticals (NASDAQ: KNSA ) raises FY2026 sales outlook from $930.000 million-$945.000 million to $980.000 million-$995.000 million vs $940.106 million estimate. EARNINGS | Jul 28, 2026, 11:30 AM UTC L BA BOEING 2Q CORE LOSS/SHR 76C, EST. LOSS/SHR 28C || 2Q ADJ FREE CASH FLOW $631M, EST. NEGATIVE $331.4M || 2Q CORE LOSS/SHR 76C || 2Q COMMER BA BOEING 2Q CORE LOSS/SHR 76C, EST. LOSS/SHR 28C || 2Q ADJ FREE CASH FLOW $631M, EST. NEGATIVE $331.4M || 2Q CORE LOSS/SHR 76C || 2Q COMMERCIAL AIRPLANES REV. $11.75B, EST. $11.63B || 2Q REV. $24.56B, EST. $24.26B EQUITY | Jul 28, 2026, 11:30 AM UTC L KNSA Kiniksa Pharmaceuticals RESULTS: Q2, Q2 operating expenses $216.406M, Q2 Net Income $25.432M, Q2 pretax profit $31.145M, Kiniksa Pharma KNSA Kiniksa Pharmaceuticals RESULTS: Q2, Q2 operating expenses $216.406M, Q2 Net Income $25.432M, Q2 pretax profit $31.145M, Kiniksa Pharmaceuticals Earnings Notes:, - Kiniksa Pharmaceuticals Q2 product REV $243.6M EARNINGS | Jul 28, 2026, 11:30 AM UTC L XIFR - XPLR Infrastructure, LP second-quarter 2026 financial results available on company's website XIFR - XPLR Infrastructure, LP second-quarter 2026 financial results available on company's website EARNINGS | Jul 28, 2026, 11:30 AM UTC L ZENA - ZenaTech’s ZenaDrone Begins Testing Phase for Interceptor P-1 Counter-UAS Drone Platform ZENA - ZenaTech’s ZenaDrone Begins Testing Phase for Interceptor P-1 Counter-UAS Drone Platform EQUITY | Jul 28, 2026, 11:30 AM UTC L DDD - 3D Systems Enables First FDA Clearance for Implant from a Point-of-Care Institution DDD - 3D Systems Enables First FDA Clearance for Implant from a Point-of-Care Institution REGULATION | Jul 28, 2026, 11:30 AM UTC H HUBB Hubbell RESULTS: Q2, Q2 REV $1,711.8M vs. EST $1.653B, Q2 EPS $4.52, Q2 Net Income $242.2M, Q2 ADJ EPS $5.52 vs. EST $5.38, Q2 operatin HUBB Hubbell RESULTS: Q2, Q2 REV $1,711.8M vs. EST $1.653B, Q2 EPS $4.52, Q2 Net Income $242.2M, Q2 ADJ EPS $5.52 vs. EST $5.38, Q2 operating margin 20.4%, Q2 ADJ operating margin 23.9%, Q2 free cash flow $213M, Hubbell EARNINGS | Jul 28, 2026, 11:30 AM UTC L BA FAA proposes to adopt new AD for Boeing planes, to inspect seat installation BA FAA proposes to adopt new AD for Boeing planes, to inspect seat installation EQUITY | Jul 28, 2026, 11:30 AM UTC L CAG - Conagra Brands Provides Senior Leadership Update CAG - Conagra Brands Provides Senior Leadership Update EQUITY | Jul 28, 2026, 11:30 AM UTC L HSCS Fortitude Energizes 12 MW Grand Island, Nebraska Facility, Expanding Owned-and-Operated Power Portfolio HSCS Fortitude Energizes 12 MW Grand Island, Nebraska Facility, Expanding Owned-and-Operated Power Portfolio EQUITY | Jul 28, 2026, 11:30 AM UTC H BA Boeing RESULTS: Q2, Q2 adj. EPS $-0.76 vs EST $-0.30, Q2 REV $24.56B vs EST $24.25B, Boeing Q2-end backlog $715B, Q2 non-GAAP free cash f BA Boeing RESULTS: Q2, Q2 adj. EPS $-0.76 vs EST $-0.30, Q2 REV $24.56B vs EST $24.25B, Boeing Q2-end backlog $715B, Q2 non-GAAP free cash flow $631M, Boeing Earnings Notes:, Q2 results include $280M loss on air force on EARNINGS | Jul 28, 2026, 11:30 AM UTC L PSTV - Plus Therapeutics Announces Scientific Presentations and Sponsored Symposium at 2026 SNO/ASCO CNS Metastases Conference - Click For R PSTV - Plus Therapeutics Announces Scientific Presentations and Sponsored Symposium at 2026 SNO/ASCO CNS Metastases Conference EQUITY | Jul 28, 2026, 11:30 AM UTC L ELAB - PMGC Holdings Inc. Announces Strategic Investment in Precision Aerospace & Defense Group and Long-Term Aerospace and Defense Manufact ELAB - PMGC Holdings Inc. Announces Strategic Investment in Precision Aerospace & Defense Group and Long-Term Aerospace and Defense Manufacturing Agreement Through A&B Aerospace Inc. EQUITY | Jul 28, 2026, 11:30 AM UTC L NICH - Why is NICH Moving This Fast? NutraVeri Signals Factory-Aligned Expansion After Early InTheZone Feedback from Military and Former NFL NICH - Why is NICH Moving This Fast? NutraVeri Signals Factory-Aligned Expansion After Early InTheZone Feedback from Military and Former NFL Communities EQUITY | Jul 28, 2026, 11:30 AM UTC L HBIO - Harvard Bioscience Schedules Second Quarter 2026 Earnings Conference Call for August 11, 2026 at 8:00 AM ET HBIO - Harvard Bioscience Schedules Second Quarter 2026 Earnings Conference Call for August 11, 2026 at 8:00 AM ET EARNINGS | Jul 28, 2026, 11:30 AM UTC L ALGR KM00 ALGRF - Algo Grande Provides Phase II Drill Update at Adelita; Copper Intersected in Skarn and Andesitic Porphyry at Cerro Grande ALGR KM00 ALGRF - Algo Grande Provides Phase II Drill Update at Adelita; Copper Intersected in Skarn and Andesitic Porphyry at Cerro Grande COMMODITIES | Jul 28, 2026, 11:30 AM UTC L ESAU ESAUF Z7D - ESGold Receives Exploration Authorization From Québec Government and Continues to Advance Its Permitted Tailings Reprocessi ESAU ESAUF Z7D - ESGold Receives Exploration Authorization From Québec Government and Continues to Advance Its Permitted Tailings Reprocessing Project EQUITY | Jul 28, 2026, 11:30 AM UTC L TRVI - Trevi Therapeutics to Participate in Upcoming August Conferences TRVI - Trevi Therapeutics to Participate in Upcoming August Conferences EQUITY | Jul 28, 2026, 11:30 AM UTC L NSRX - Nasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O'Grady as Chief Executive Officer to Lead Strategic Growth - Click NSRX - Nasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O'Grady as Chief Executive Officer to Lead Strategic Growth EQUITY | Jul 28, 2026, 11:30 AM UTC